MBX · MBX Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Patrick J. Heron Director | ▲ Buy | Open Market | 5,219,440 Shares held | 9/26/2025 | View profile |
| Frazier Life Sciences X, L.P. | ▲ Buy | Open Market | 4,552,774 Shares held | 9/16/2024 | View profile |
| Ali Behbahani Director | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Scott D. Sandell 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Carmen Chang 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Edward T. Mathers Director | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| BASKETT FOREST 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Makhzoumi Mohamad 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Florence Anthony A. Jr. 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Yang Rick 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Walker Paul Edward 10% Owner | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| New Enterprise Associates 17, L.P. | ▲ Buy | Open Market | 3,614,486 Shares held | 9/16/2024 | View profile |
| Aynechi Tiba | ▲ Buy | Open Market | 2,136,335 Shares held | 9/16/2024 | View profile |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | ▼ Sell | Other | 1,790,122 Shares held | 9/16/2024 | View profile |
| ORBIMED ADVISORS LLC Director | ▲ Buy | Open Market | 747,887 Shares held | 2/18/2025 | View profile |
| Carl L. Gordon Director | ▲ Buy | Open Market | 747,887 Shares held | 2/18/2025 | View profile |
| Hawryluk P. Kent President & CEO | ▼ Sell | Open Market | 727,667 Shares held | 5/6/2026 | View profile |
| CORNELIUS JAMES M | ▼ Sell | Other | 102,082 Shares held | 9/16/2024 | View profile |
| Hoerter Steven L. | ▲ Buy | Grant | 82,938 Shares held | 8/3/2026 | View profile |
| John W. Smither Chief Financial Officer | ▲ Buy | Grant | 28,000 Shares held | 8/3/2026 | View profile |
| Pescovitz Ora H. | ▲ Buy | Open Market | 24,329 Shares held | 4/8/2025 | View profile |
| Bartram Richard Chief Financial Officer | ▲ Buy | Grant | 15,000 Shares held | 2/2/2026 | View profile |
| Azoulay Salomon Chief Medical Officer | ▼ Sell | Open Market | 14,399 Shares held | 8/4/2026 | View profile |
Transaction History
| Azoulay Salomon | ▼ Sell | Open Market | 370 | $24K | 8/4/2026 |
| John W. Smither | ▲ Buy | Grant | 28,000 | $0 | 8/3/2026 |
| Hoerter Steven L. | ▲ Buy | Grant | 71,000 | $0 | 8/3/2026 |
| Azoulay Salomon | ▲ Buy | Option Exercise | 55,000 | $575K | 5/8/2026 |
| Azoulay Salomon | ▼ Sell | Open Market | 55,000 | $2.1M | 5/8/2026 |
| Azoulay Salomon | ▲ Buy | Option Exercise | 15,003 | $240K | 5/8/2026 |
| Azoulay Salomon | ▼ Sell | Open Market | 15,003 | $575K | 5/8/2026 |
| Hawryluk P. Kent | ▼ Sell | Open Market | 607 | $18K | 5/6/2026 |
| Azoulay Salomon | ▼ Sell | Open Market | 231 | $7K | 5/6/2026 |
| Hoerter Steven L. | ▲ Buy | Grant | 11,938 | $0 | 5/1/2026 |
| Hawryluk P. Kent | ▲ Buy | Open Market | 18,500 | $526K | 3/13/2026 |
| Hawryluk P. Kent | ▲ Buy | Option Exercise | 28,768 | $460K | 2/26/2026 |
| Hawryluk P. Kent | ▲ Buy | Grant | 35,250 | $0 | 2/2/2026 |
| Azoulay Salomon | ▲ Buy | Grant | 15,000 | $0 | 2/2/2026 |
| Bartram Richard | ▲ Buy | Grant | 15,000 | $0 | 2/2/2026 |
| Hawryluk P. Kent | ▲ Buy | Option Exercise | 182,859 | $594K | 10/24/2025 |
| Hawryluk P. Kent | ▲ Buy | Open Market | 20,000 | $273K | 10/20/2025 |
| Hoerter Steven L. | ▲ Buy | Open Market | 20,000 | $265K | 10/17/2025 |
| Patrick J. Heron | ▲ Buy | Open Market | 666,666 | $12.0M | 9/26/2025 |
| Pescovitz Ora H. | ▲ Buy | Open Market | 7,693 | $45K | 4/8/2025 |
| Carl L. Gordon | ▲ Buy | Open Market | 94,100 | $1.0M | 2/18/2025 |
| Carl L. Gordon | ▲ Buy | Open Market | 49,070 | $532K | 2/18/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 49,070 | $532K | 2/18/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 94,100 | $1.0M | 2/18/2025 |
| Carl L. Gordon | ▲ Buy | Open Market | 17,962 | $178K | 2/14/2025 |
| Carl L. Gordon | ▲ Buy | Open Market | 29,540 | $291K | 2/14/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 17,962 | $178K | 2/14/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 29,540 | $291K | 2/14/2025 |
| Hawryluk P. Kent | ▲ Buy | Open Market | 50,000 | $535K | 2/4/2025 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| New Enterprise Associates 17, L.P. | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Frazier Life Sciences X, L.P. | ▲ Buy | Open Market | 625,000 | $10.0M | 9/16/2024 |
| Patrick J. Heron | ▲ Buy | Open Market | 625,000 | $10.0M | 9/16/2024 |
| Carl L. Gordon | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Aynechi Tiba | ▲ Buy | Open Market | 750,000 | $12.0M | 9/16/2024 |
| Carl L. Gordon | ▼ Sell | Other | 2,658,428 | — | 9/16/2024 |
| Aynechi Tiba | ▼ Sell | Other | 1,386,335 | — | 9/16/2024 |
| CORNELIUS JAMES M | ▼ Sell | Other | 102,082 | — | 9/16/2024 |
| Hawryluk P. Kent | ▼ Sell | Other | 283,846 | — | 9/16/2024 |
| Hawryluk P. Kent | ▼ Sell | Other | 115,914 | — | 9/16/2024 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 250,000 | $4.0M | 9/16/2024 |
| Patrick J. Heron | ▼ Sell | Other | 3,927,774 | — | 9/16/2024 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| New Enterprise Associates 17, L.P. | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 403,787 | — | 9/16/2024 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 2,658,428 | — | 9/16/2024 |
| Frazier Life Sciences X, L.P. | ▼ Sell | Other | 3,927,774 | — | 9/16/2024 |
| Carl L. Gordon | ▼ Sell | Other | 403,787 | — | 9/16/2024 |
| Edward T. Mathers | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Edward T. Mathers | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Florence Anthony A. Jr. | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Makhzoumi Mohamad | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Makhzoumi Mohamad | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Makhzoumi Mohamad | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Walker Paul Edward | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Walker Paul Edward | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Walker Paul Edward | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Yang Rick | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Yang Rick | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Yang Rick | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Scott D. Sandell | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Scott D. Sandell | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Scott D. Sandell | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Carl L. Gordon | ▲ Buy | Open Market | 250,000 | $4.0M | 9/16/2024 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | ▼ Sell | Other | 1,386,335 | — | 9/16/2024 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | ▼ Sell | Other | 403,787 | — | 9/16/2024 |
| Edward T. Mathers | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| BASKETT FOREST | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| BASKETT FOREST | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| BASKETT FOREST | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Ali Behbahani | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Ali Behbahani | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Ali Behbahani | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Carmen Chang | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Carmen Chang | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
| Carmen Chang | ▲ Buy | Open Market | 500,000 | $8.0M | 9/16/2024 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 1,023,103 | — | 9/16/2024 |
| Florence Anthony A. Jr. | ▼ Sell | Other | 2,091,383 | — | 9/16/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised
MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.
MBX Biosciences to Attend Investor Conferences, Analyst Target Raised. MBX Biosciences will join several investor conferences in November, offering a chance for investors to hear about its pipeline. Stifel has kept a positive stance and lifted its target price to $84. Analysts are debating whether the recent 257% jump has pushed the stock above fair value, while others question if the pullback from a strong year run still leaves room for upside.